BiotechTube

Cryotherapy + Tirbanibulin

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Keratosis

Conditions

Keratosis, Actinic Keratoses

Trial Timeline

Nov 30, 2025 → Nov 30, 2027

NCT ID
NCT07273656

About Cryotherapy + Tirbanibulin

Cryotherapy + Tirbanibulin is a phase 3 stage product being developed by Almirall for Keratosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07273656. Target conditions include Keratosis, Actinic Keratoses.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07273656Phase 3Recruiting

Competing Products

20 competing products in Keratosis

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
Investigational Treatment + Active comparatorNovartisPhase 2
52
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
Imiquimod + DiclofenacViatrisApproved
82
Imiquimod 5 % CreamViatrisPhase 2
49
Aldara (Imiquimod)ViatrisPhase 3
74
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
80
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80
LAS41005AlmirallPhase 2
47
TirbanibulinAlmirallPhase 3
72

Other Products from Almirall

TildrakizumabApproved
80
Tiotropium + AclidiniumApproved
80
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved
80
Pidotimod + PlaceboApproved
80
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelApproved
80